UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
UroGen Pharma Ltd. (Nasdaq: URGN) will report its second quarter 2021 financial results on August 4, 2021, before market opening. The company will hold a live audio webcast and conference call at 8:30 AM Eastern Time to discuss these results. UroGen specializes in biopharmaceutical solutions for specialty cancers and urologic diseases, with its first commercial product being UGN-102, an investigational treatment for low-grade non-muscle invasive bladder cancer. More information can be accessed through UroGen's investor relations webpage.
- Upcoming Q2 2021 financial results report could showcase potential revenue growth.
- UroGen's investigational treatment UGN-102 aims to provide non-surgical tumor ablation options.
- Market reaction to earnings report may influence stock performance negatively if results are underwhelming.
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 1539383
About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005159/en/
FAQ
When will UroGen report its Q2 2021 financial results?
What time is the UroGen conference call for Q2 2021 financial results?
What is UGN-102?
Where can I access the UroGen Q2 2021 financial results webcast?
